Sector
PharmaceuticalsOpen
₹248.2Prev. Close
₹247.95Turnover(Lac.)
₹7,230.29Day's High
₹249.8Day's Low
₹236.9552 Week's High
₹358.752 Week's Low
₹157.2Book Value
₹31.14Face Value
₹1Mkt Cap (₹ Cr.)
10,875.93P/E
57.94EPS
4.15Divi. Yield
0.3319 Aug 2024
12:00 AM
AGM
Announcement Date: 19 Aug, 2024
8 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
The block deal has been launched at a floor price of ₹249.95 per share, signaling a strategic partial exit by the investor.
Relonchem Ltd has secured Marketing Authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets
The US Food and Drug Administration (FDA) approved the pharmaceutical company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 45.32 | 45.32 | 134.03 | 40.93 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,177.39 | 1,066.01 | 650.64 | 558.79 |
Net Worth | 1,222.71 | 1,111.33 | 784.67 | 599.72 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 599.54 | 433.41 | 294.66 | 215.83 |
yoy growth (%) | 38.33 | 47.08 | 36.51 | -39.73 |
Raw materials | -337.91 | -243.03 | -169.34 | -112.37 |
As % of sales | 56.36 | 56.07 | 57.47 | 52.06 |
Employee costs | -54.63 | -48.5 | -45.85 | -39.77 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 124.32 | 52.72 | 16.65 | 11.94 |
Depreciation | -15.19 | -11.64 | -12.25 | -15 |
Tax paid | -25.94 | -14.82 | -4.22 | -0.4 |
Working capital | 82.13 | -10.16 | 7.89 | 46.78 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 38.33 | 47.08 | 36.51 | -39.73 |
Op profit growth | 59.06 | 96.13 | 48.84 | -76.42 |
EBIT growth | 116.05 | 146.78 | 47.96 | -83.19 |
Net profit growth | 159.55 | 205 | 7.64 | -83.84 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 2,622.85 | 2,177.41 | 1,852.14 | 1,490.84 | 1,376.18 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,622.85 | 2,177.41 | 1,852.14 | 1,490.84 | 1,376.18 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 70.38 | 50.42 | 59.31 | 41.85 | 6.69 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,647.6 | 92.29 | 3,95,254.45 | 2,000.46 | 0.97 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,493 | 78.03 | 1,72,374.06 | 667 | 0.46 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,484 | 24.33 | 1,19,795.19 | 1,485.4 | 1.08 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,326.1 | 20.69 | 1,10,689.83 | 1,200.7 | 0.6 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,164 | 56.27 | 1,07,213.01 | 474 | 1.01 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Mark Saldanha
Company Sec. & Compli. Officer
Harshavardhan Panigrahi
Non-Exec. & Independent Dir.
Seetharama Raju Buddharaju
Whole-time Director
Sandra Saldanha
Non-Exec. & Independent Dir.
Digant Mahesh Parikh
Whole-time Director
Varddhman Vikramaditya Jain
Non-Exec. & Independent Dir.
Abhinna Sundar Mohanty
Non Executive Director
Sunny Sharma
Independent Director
Shailaja Vardhan
Additional Director
Srinivas Mishra
11th Flr GRANDEUR Oshiwara,
Veera Desai Extn Rd Andheri(W),
Maharashtra - 400053
Tel: 91-22-40012000
Website: http://www.marksanspharma.com
Email: companysecretary@marksanspharma.com ; info@marksan
Office No 56-2,
Pinnacle Busine.Park, Mahakali Caves Road,
Mumbai - 400093
Tel: 91-22-62638200
Website: www.bigshareonline.com
Email: investor@bigshareonline.com
Summary
Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limi...
Read More
Reports by Marksans Pharma Ltd
What is the Marksans Pharma Ltd share price today?
What is the Market Cap of Marksans Pharma Ltd?
What is the PE and PB ratio of Marksans Pharma Ltd?
What is the 52 Week High and Low of Marksans Pharma Ltd?
What is the CAGR of Marksans Pharma Ltd?
What is the shareholding pattern of Marksans Pharma Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
